Druggable targets in cytokine release syndromes

Abstract

Bispecific T-cell engagers and CAR T-cells share the problem of eliciting acute systemic inflammation episodes known as Cytokine Release Syndrome (CRS).

Knowledge on the sequential waves of cytokines that can be neutralized with clinically available agents is crucial to prevent or treat this condition without jeopardizing the antitumor therapeutic outcome.

CITA DEL ARTÍCULO  Clin Cancer Res. 2023 Sep 1. doi: 10.1158/1078-0432.CCR-23-1975